Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

@inproceedings{Houde2010ChronicRT,
  title={Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue},
  author={Vanessa P. Houde and Sophie Br{\^u}l{\'e} and William T Festuccia and P G Blanchard and Kerstin Bellmann and Yves Deshaies and Andr{\'e} Marette},
  booktitle={Diabetes},
  year={2010}
}
OBJECTIVE The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 156 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

HOUDE AND ASSOCIATES diabetes.diabetesjournals.org DIABETES

  • DD Sarbassov, SM Ali, S Sengupta, JH Sheen, PP Hsu, AF V.P. Bagley
  • VOL. 59,
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…